GLAXOSMITHKLINE PLC 4
4 · Lyell Immunopharma, Inc. · Filed Jun 23, 2021
Insider Transaction Report
Form 4
GLAXOSMITHKLINE PLC
10% Owner
Transactions
- Conversion
Common Stock
2021-06-21+30,253,189→ 30,253,189 total(indirect: See Footnote) - Conversion
Series AA Preferred Stock
2021-06-21−30,253,189→ 0 total(indirect: See Footnote)→ Common Stock (30,253,189 underlying)
Footnotes (2)
- [F1]The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").